News and Trends 14 Jul 2016
Institut Pasteur & Austrian Biotech also join the World Zika Vaccine Plan
Themis is a Vienna-based vaccine developer. Together with the Institut Pasteur, it is now planning to use a measles vaccine construct to develop and start Zika vaccine trials within the next 12 months. Themis has successfully extended its existing license agreement with Institut Pasteur in Paris, which grants the company a broad access to a well-established virus vaccine vector technology. The […]
